AAPL 208.72 0.168% MSFT 388.5148 0.3137% NVDA 110.49 3.8147% GOOGL 162.58 2.0718% GOOG 164.7 2.0004% AMZN 187.93 0.7451% META 545.87 2.3858% AVGO 191.75 1.9134% LLY 870.695 1.2754% TSLA 285.6351 10.0671% TSM 164.7921 0.3728% V 334.98 -0.2174% JPM 243.11 -0.6254% UNH 418.56 -1.3412% NVO 61.81 -1.3093% WMT 94.725 -1.1634% LVMUY 114.14 -0.105% XOM 108.25 -0.3498% LVMHF 566.0 0.7347% MA 532.36 -0.5789%
Last update at 2025-01-26T19:02:55.523371Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Income before tax | -11.91922M | -11.37983M | -5.81181M | -8.06064M | -5.90820M |
| Minority interest | - | - | - | - | - |
| Net income | -11.91922M | -11.37983M | -5.81181M | -8.06064M | -5.90820M |
| Selling general administrative | 0.55M | 3.05M | 2.92M | 3.56M | 4.46M |
| Selling and marketing expenses | 1.38M | 1.32M | 1.14M | 0.84M | 0.63M |
| Gross profit | 2.91M | 1.48M | 1.69M | 0.47M | 0.56M |
| Reconciled depreciation | 0.08M | 0.10M | 0.09M | 0.10M | 0.11M |
| Ebit | -11.91194M | -11.46270M | -5.91614M | -8.20341M | -6.66629M |
| Ebitda | -11.90036M | -11.36750M | -5.82693M | -8.10009M | -6.55869M |
| Depreciation and amortization | 0.01M | 0.10M | 0.09M | 0.10M | 0.11M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -11.83251M | -13.34497M | -7.61123M | -8.68328M | -6.66629M |
| Other operating expenses | 14.80M | 13.34M | 7.61M | 8.68M | 6.67M |
| Interest expense | 0.00360M | 0.00815M | 0.01M | 0.01M | 0.01M |
| Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 0.62M | 0.38M | 0.03M | 0.00418M | 0.03M |
| Net interest income | 0.61M | 0.38M | 0.02M | -0.00655M | 0.02M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -2.35200M | -0.37677M | -0.02227M | 0.00655M | -0.01799M |
| Total revenue | 2.97M | 1.58M | 1.78M | 0.58M | 0.67M |
| Total operating expenses | 14.74M | 13.34M | 7.61M | 8.68M | 6.67M |
| Cost of revenue | 0.06M | 0.10M | 0.09M | 0.10M | 0.11M |
| Total other income expense net | -0.08671M | -0.09482M | -0.06770M | -0.05844M | 0.74M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -11.91922M | -11.37983M | -5.81181M | -8.06064M | -5.90820M |
| Net income applicable to common shares | - | -11.37983M | -5.81181M | -8.06064M | -5.90820M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total assets | 14.53M | 12.84M | 22.44M | 7.00M | 5.35M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.04M | - | 0.53M | - | 0.26M |
| Total liab | 5.17M | 2.87M | 1.30M | 1.27M | 0.82M |
| Total stockholder equity | 9.36M | 9.98M | 21.14M | 5.73M | 4.53M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1.38M | 1.70M | 0.74M | 0.81M | 0.58M |
| Common stock | 109.37M | 98.26M | 98.13M | 77.03M | 69.15M |
| Capital stock | 109.37M | 98.26M | 98.13M | 77.03M | 69.15M |
| Retained earnings | -101.73024M | -92.28922M | -80.90939M | -75.09758M | -67.03694M |
| Other liab | - | 0.00706M | 0.00113M | 0.00012M | - |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | - | - | - | - |
| Cash | 11.87M | 10.97M | 19.23M | 6.02M | 4.06M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 5.15M | 2.81M | 1.16M | 1.05M | 0.80M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -11.82678M | -10.82516M | -19.00578M | -5.71356M | -3.92418M |
| Short term debt | 0.04M | 0.09M | 0.09M | 0.08M | 0.11M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.04M | 0.14M | 0.23M | 0.31M | 0.14M |
| Other stockholder equity | - | 4.00M | 3.92M | 3.79M | 2.42M |
| Property plant equipment | - | 0.15M | 0.22M | 0.30M | 0.14M |
| Total current assets | 14.47M | 12.69M | 22.22M | 6.70M | 5.21M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 9.98M | 21.14M | 5.73M | 4.53M |
| Short term investments | - | - | - | - | - |
| Net receivables | 2.51M | 1.66M | 1.84M | 0.60M | 0.69M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | 0.61M | - | 0.21M |
| Accounts payable | 3.73M | 1.02M | 0.33M | 0.16M | 0.11M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 1.72M | 4.00M | 3.92M | 3.79M | 2.42M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -0.00000M | - | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.06M | 0.15M | 0.22M | 0.30M | 0.14M |
| Capital lease obligations | 0.04M | 0.14M | 0.23M | 0.31M | 0.14M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Investments | -0.00361M | -0.02929M | -0.00391M | -0.00835M | -0.01026M |
| Change to liabilities | - | 1.76M | 0.03M | 0.22M | -0.25981M |
| Total cashflows from investing activities | - | -0.02929M | -0.00391M | -0.00835M | -0.01026M |
| Net borrowings | - | -0.08530M | -0.07944M | -0.08238M | -0.09789M |
| Total cash from financing activities | 11.02M | -0.08530M | 21.02M | 7.80M | 5.11M |
| Change to operating activities | - | 0.77M | -0.99621M | 0.45M | 0.03M |
| Net income | -11.91922M | -11.37983M | -5.81181M | -8.06064M | -5.90820M |
| Change in cash | 0.90M | -8.26592M | 13.21M | 1.96M | 1.16M |
| Begin period cash flow | 10.97M | 19.23M | 6.02M | 4.06M | 2.90M |
| End period cash flow | 11.87M | 10.97M | 19.23M | 6.02M | 4.06M |
| Total cash from operating activities | -10.11585M | -8.15133M | -7.80517M | -5.83416M | -3.94536M |
| Issuance of capital stock | 11.61M | - | 22.59M | 8.50M | 5.49M |
| Depreciation | 0.08M | 0.10M | 0.09M | 0.10M | 0.11M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | -0.00000M |
| Change to account receivables | -0.83236M | 0.34M | -1.23972M | 0.09M | -0.33976M |
| Sale purchase of stock | -0.50328M | - | -1.48520M | -0.61415M | -0.28515M |
| Other cashflows from financing activities | -0.08939M | -0.08530M | -0.07944M | -0.08238M | -0.09789M |
| Change to netincome | - | 0.26M | 0.12M | 1.37M | 2.42M |
| Capital expenditures | 0.00361M | 0.03M | 0.00391M | 0.00835M | 0.01M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 1.53M | 2.87M | -2.20699M | 0.76M | -0.56484M |
| Stock based compensation | 0.20M | 0.21M | 0.12M | 1.37M | 2.42M |
| Other non cash items | -1.19260M | 0.26M | 0.12M | 1.37M | 2.42M |
| Free cash flow | -10.11946M | -8.18062M | -7.80908M | -5.84251M | -3.95562M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ATHJF Antisense Therapeutics Limited |
- -% | - | - | - | 31.21 | 7.56 | 216.75 | -2.8133 |
| ZTS Zoetis Inc |
-0.1452 0.10% | 152.15 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.25 0.90% | 27.59 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% | 133.19 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.095 0.63% | 15.02 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
L30, Collins Place, Melbourne, VIC, Australia, 3000
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark Diamond B.Sc., M.B.A., BSc, MBA, MAICD | CEO, MD & Director | NA |
| Mr. Phillip Allen Hains BBus(Acc), CA, MBA | CFO & Joint Company Sec. | 1959 |
| Dr. George Tachas | Director of Drug Discovery & Patents | NA |
| Ms. Nuket Desem | Director of Clinical and Regulatory affairs | NA |
| Dr. Anthony Filippis | Chief Commercial Officer | NA |
| Ms. Alicia Mellors | Joint Company Sec. | NA |
| Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA | CEO, MD & Director | 1973 |
| Ms. Deborah Ambrosini B.Com., F.C.A. | Company Secretary & CFO | 1974 |
| Dr. Anthony Filippis | Chief Operating Officer | NA |
| Dr. Cathryn M. Clary M.B.A., M.D. | Chief Medical Advisor | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US
CA
NZ
UK
AU
IND
Please wait processing your request...